AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Cirralto

0.035

0.000

Volume:- -

Turnover:229.21K

Market Cap:114.21M

PE:-2.19

High:0.035

Open:0.035

Low:0.035

Close:0.035

52wk High:0.035

52wk Low:0.035

Shares:3.26B

Float Shares:2.78B

Volume Ratio:0.42

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.016

EPS(LYR):-0.006

ROE:-101.54%

ROA:-16.17%

PB:10.34

PE(LYR):-5.39

Loading ...

Overview Company News Filings

Charles River Laboratories International (CRL) Cut 2026 Guidance, Is The Stock Still 11% Undervalued?

Simply Wall St.

Shiba Inu (SHIB) Re-Enters Crypto Top 30 as Exchange Reserves Plunge to 87.18 Trillion Coins

FPT.AI recognized as a High Performer in G2's Summer Reports

NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development

Monash University and ClinChoice Forge Strategic Partnership to Accelerate Clinical Development of Innovative Therapies

Locus Cell, Taiwan-Based Cell and Gene Therapy CDMO, Signs MoU with Charles River at APAC Biomanufacturing Leadership Summit

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/CRO.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CRO.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CRO.AU\",,,,,undefined,":{"symbol":"CRO.AU","market":"AU","secType":"STK","nameCN":"Cirralto","latestPrice":0.035,"timestamp":1787292000000,"preClose":0.035,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"Cirralto","floatShares":2783638959,"shares":3263000000,"eps":-0.016,"marketStatus":"Market Closed","change":0,"latestTime":"08-21 16:00:00 AEST","open":0.035,"high":0.035,"low":0.035,"amount":229213.84486759,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.016,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.035,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.4214344032954702,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CRO.AU\",,,,,undefined,":{"symbol":"CRO.AU","floatShares":2783638959,"roa":"-16.17%","roe":"-101.54%","lyrEps":-0.006499,"volumeRatio":0.4214344032954702,"shares":3263000000,"dividePrice":0,"high":0.035,"amplitude":0,"preClose":0.035,"low":0.035,"week52Low":0.035,"pbRate":"10.34","psRate":"11.03","week52High":0.035,"institutionHeld":0,"latestPrice":0.035,"eps":-0.016,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.016,"open":0.035,"prevYearClose":0.035,"prevWeekClose":0.035,"prevMonthClose":0.035,"prevQuarterClose":0.035,"fiveDayClose":0.035,"twentyDayClose":0.035,"sixtyDayClose":0.035},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CRO.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CRO.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CRO.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660641757","title":"Charles River Laboratories International (CRL) Cut 2026 Guidance, Is The Stock Still 11% Undervalued?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660641757","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660641757?lang=en_us&edition=fundamental","pubTime":"2026-08-19 13:12","pubTimestamp":1787116362,"startTime":"0","endTime":"0","summary":"Charles River Laboratories International (CRL) cut its 2026 earnings guidance after reporting a second quarter net loss and slightly lower revenue. The company also continued its share repurchase program during the same period.\nSee our latest analysis for Charles River Laboratories International.\nDespite the cut to 2026 earnings guidance and the recent quarterly net loss, Charles River Laboratories International’s share price has risen strongly over recent months, with a 30-day share price...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-international-crl-cut-2026-guidan","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-international-crl-cut-2026-guidan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4530","LU0757428866.USD","BK4225","LU1815336091.USD","LU0128526141.USD","IE00BFMHRM44.USD","BK4585","LU0029874061.USD","BK4121","CRL","CRL.AU","NHP","CRO.AU","LU0390134368.USD","BK7500","BK7095","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647355542","title":"Shiba Inu (SHIB) Re-Enters Crypto Top 30 as Exchange Reserves Plunge to 87.18 Trillion Coins","url":"https://stock-news.laohu8.com/highlight/detail?id=2647355542","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647355542?lang=en_us&edition=fundamental","pubTime":"2026-06-29 16:51","pubTimestamp":1782723060,"startTime":"0","endTime":"0","summary":"Shiba Inu (SHIB) token has successfully returned to the top 30 strongest cryptocurrencies in the world, pushing out competitors thanks to coordinated buying by large-capital investors. Despite the hea","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/shiba-inu-shib-re-enters-crypto-top-30-as-exchange-reserves-plunge-to-8718-trillion-coins","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/shiba-inu-shib-re-enters-crypto-top-30-as-exchange-reserves-plunge-to-8718-trillion-coins","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["BK7500","CRO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638620577","title":"FPT.AI recognized as a High Performer in G2's Summer Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2638620577","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638620577?lang=en_us&edition=fundamental","pubTime":"2026-05-27 15:47","pubTimestamp":1779868020,"startTime":"0","endTime":"0","summary":"HANOI, Vietnam, May 27, 2026 /PRNewswire/ -- G2, the world's leading software marketplace and peer-review platform serving more than 200 million business decision-makers annually, has recognized FPT.AI as a High Performer in the AI Agent category.The ranking is based entirely on verified customer reviews and evaluates vendors across multiple criteria, including ease of implementation, integration capabilities, customer satisfaction, product direction, and overall business value. In addition to its global recognition, FPT.AI was also acknowledged as a High Performer across the Asia Pacific region, further reinforcing its growing presence and credibility in the enterprise AI market.Widely regarded as one of the software industry's most trusted benchmarks, G2's Reports reflect authentic customer experiences rather than analyst opinions alone. To qualify as a High Performer, platforms must demonstrate strong customer satisfaction while delivering reliable operational performance and measur","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2988567/High_Performer_in_G2_Summer_Reports.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2988567/High_Performer_in_G2_Summer_Reports.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/fptai-recognized-as-a-high-performer-in-g2s-summer-reports-302782847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTY","BK4023","BK4587","AIPO","CHAT","CRO.AU","BK4588","BK4551","BK7500","BK4528","BK4543","AIYY","BK4585","AGIX","AI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624551293","title":"NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2624551293","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624551293?lang=en_us&edition=fundamental","pubTime":"2026-04-01 07:00","pubTimestamp":1774998000,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J. and TOKYO, April 1, 2026 /PRNewswire/ -- NJ Bio, Inc. , a leading provider of integrated drug discovery and development services and Ajinomoto BioPharma Services , a leading provider of biopharmaceutical manufacturing services and platform technologies, today announced a research collaboration to expand access to AJICAP, Aji BioPharma's sitespecific conjugation platform for NJ Bio's discoverystage and early development clients. This collaboration broadens NJ Bio's advanced antibody conjugation and linker capabilities, supporting the development of nextgeneration antibody–drug conjugates  and other targeted therapeutics.This partnership will expand access to nextgeneration antibody conjugation capabilities for biopharma innovators. Through the collaboration, NJ Bio will integrate the AJICAP platform into its discovery and development workflows, offering clients a robust and highly reproducible approach for sitespecific conjugation of cytotoxic and noncytotoxic payloads t","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2947092/Bio_Aji_BioPharma_Services_Collaboration.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2947092/Bio_Aji_BioPharma_Services_Collaboration.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/nj-bio-inc-and-ajinomoto-biopharma-services-enter-into-collaboration-to-strengthen-support-for-antibodydrug-conjugate-development-302730700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","CDMO","BK4080","BK7500","BK4231","BK4139","ADC.AU","ADC","CRO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621722994","title":"Monash University and ClinChoice Forge Strategic Partnership to Accelerate Clinical Development of Innovative Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2621722994","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621722994?lang=en_us&edition=fundamental","pubTime":"2026-03-23 14:15","pubTimestamp":1774246500,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, March 23, 2026 /PRNewswire/ -- Monash University and ClinChoice Inc, a leading global clinical Contract Research Organization  focused on innovative therapeutics, today announced a strategic partnership designed to fast-track early-phase clinical trials and bring groundbreaking health innovations and discoveries closer to patients worldwide.Each organization brings distinct strengths to healthcare innovation, and both share a clear commitment to improving health and wellbeing for patients around the world.Monash is a top 50 global university, and is Australia's largest university with a global presence across the Indo-Pacific, Europe and the US.","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2939699/image.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2939699/image.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/monash-university-and-clinchoice-forge-strategic-partnership-to-accelerate-clinical-development-of-innovative-therapies-302721802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XJO.AU","XAO.AU","XKO.AU","BK7500","CRO.AU","AAQC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618972579","title":"Locus Cell, Taiwan-Based Cell and Gene Therapy CDMO, Signs MoU with Charles River at APAC Biomanufacturing Leadership Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2618972579","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618972579?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:46","pubTimestamp":1773272760,"startTime":"0","endTime":"0","summary":"SINGAPORE, March 12, 2026 /PRNewswire/ -- Locus Cell Co., Ltd. , a Taiwan-based cell and gene therapy  Contract Development and Manufacturing Organization , and Charles River Laboratories , a global contract research organization  providing drug development support and biologics testing solutions, have signed a Memorandum of Understanding  during the APAC Biomanufacturing Leadership Summit 2026 in Singapore.Sean Chang , CEO of Locus Cell, and Nadiya Kravchuk , Senior Director of APAC Biologics Manufacturing at Charles River Laboratories, at the Memorandum of Understanding  signing during the APAC Biomanufacturing Leadership Summit 2026 in Singapore. Photo courtesy of Charles River Laboratories.The Summit, positioned as the flagship APAC biomanufacturing forum, convened regional executives, investors, regulatory experts, and scientists under the theme \"Shaping the Region's Bioproduction Landscape – From Scale-Up Innovation to Quality Compliance.\" Discussions centered on strengthening re","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2932147/image.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2932147/image.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/locus-cell-taiwan-based-cell-and-gene-therapy-cdmo-signs-mou-with-charles-river-at-apac-biomanufacturing-leadership-summit-302711618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDMO","BK4139","SMMF","BK4211","BK7500","CRO.AU","APAC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}